Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: A meta-analysis

International Journal of Neuropsychopharmacology

Volumn 16, Issue 6, 2013, Pages 1259-1266

  Kishi, Taro ^a   Meltzer, Herbert Y ^b   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

5 HT1A receptor partial agonist; buspirone; discontinuation rate; efficacy; meta analysis; psychosis; schizophrenia; systematic review; tandospirone

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; AZAPIRONE; BIPERIDEN; BUSPIRONE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SULPIRIDE; TANDOSPIRONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

DATA COLLECTION METHOD; HUMAN; MENTAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREND STUDY;

ADULT; ANTIPSYCHOTIC AGENTS; BUSPIRONE; CONFIDENCE INTERVALS; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; ONLINE SYSTEMS; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEROTONIN RECEPTOR AGONISTS;

EID: 84878828568     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000151     Document Type: Review

References (38)

1. Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784-788.
2. Bardin L, Auclair A, Kleven MS, Prinssen EP, Koek W, Newman-Tancredi A, Depoortere R (2007) Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: Comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 18:103-118.
3. Beltman MW, Voshaar RC, Speckens AE (2010) Cognitive-behavioural therapy for depression in people with a somatic disease: Meta-analysis of randomised controlled trials. Br J Psychiatry 197:11-19.
4. Cadieux RJ (1996) Azapirones: an alternative to benzodiazepines for anxiety. Am Fam Physician 53:2349-2353.
5. Carvalho AF, Machado JR, Cavalcante JL (2009) Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 22:7-12.
6. Cohn LD, Becker BJ (2003) How meta-analysis increases statistical power. Psychol Methods 8:243-253.
7. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
8. Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S (2010) A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol 30:678-682.
9. Hensler JG (2003) Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 72:1665-1682.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560.
11. Horiguchi M, Meltzer HY (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology 221:205-215.
12. Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT (1A) partial agonist. Neuropsychopharmacology 37:2175-2183.
13. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23:436-440.
14. Jackson HC, Nutt DJ (1992) Effects of benzodiazepine receptor inverse agonists on locomotor activity and exploration in mice. Eur J Pharmacol 221:199-203.
15. Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): Rationale and standardisation. Br J Psychiatry Suppl. 7:59-67.
16. Le Francois B, Czesak M, Steubl D, Albert PR (2008) Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55:977-985.
17. Lopez-Munoz F, Rubio G (2011) Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia. Evid Based Ment Health 14:96.
18. Matheson GK, Pfeifer DM, Weiberg MB, Michel C (1994) The effects of azapirones on serotonin1A neurons of the dorsal raphe. Gen Pharmacol 25:675-683.
19. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197.
20. Meltzer HY, Massey BW(2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11:59-67.
21. Meltzer HY, Sumiyoshi T (2008) Does stimulation of 5-HT (1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98-102.
22. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
23. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104.
24. Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S (1987) Tiaspirone in schizophrenia. J Clin psychopharmacol 7:98-101.
25. Newman-Tancredi A, Kleven MS (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 216:451-473.
26. Onrust SV, McClellan K (2001) Perospirone. CNS Drugs 15:329-337; discussion 338.
27. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812.
28. Piskulic D, Olver JS, Maruff P, Norman TR (2009) Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. Hum Psychopharmacol 24:437-446.
29. Rigdon GC,Weatherspoon JK (1992) 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther 263:486-493.
30. Sumiyoshi T, Higuchi Y (2012) Facilitative effect of serotonin1A receptor agonists on cognition in patients with schizophrenia. Curr Med Chem 20:357-362.
31. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725.
32. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY (2007) Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 95:158-168.
33. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996) Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708:209-214.
34. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB (2002) Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59:514-520.
35. Taylor DP, Moon SL (1991) Buspirone and related compounds as alternative anxiolytics. Neuropeptides 19 Suppl:15-19.
36. Wedzony K, Mackowiak M, Fijal K, Golembiowska K (1996a) Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists. Synapse 24:240-247.
37. Wedzony K, Mackowiak M, Fijal K, Golembiowska K (1996b) Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Eur J Pharmacol 305:73-78.
38. Winters BD, Reid JM (2010) A distributed cortical representation underlies crossmodal object recognition in rats. J Neurosci 30:6253-6261.